Regulatory delays at Bengaluru and MDI facilities
US FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.
high · management_commentaryCipla Ltd — Q3 FY25
Cipla reported Q3 FY25 revenue of INR 7,073 crore (+8% YoY) and EBITDA margin of 28% (+184bps YoY), driven by strong India (10% growth), South Africa (21% ZAR), and EMEU (20% US...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lanreotide supply disruption recovery timeline
Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.
medium · analyst_questionUS tariff policy uncertainty
Potential US tariffs on pharmaceutical imports could impact margins; management noted de-risking via US facilities but awaits policy clarity.
medium · analyst_questionGeneric Revlimid revenue decline
Revlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction.
high · data_observation